References
- Lawrence RC, Helmick CG, Arnett FC, et al. Estimates of the prevalence of arthritis and selected musculoskeletal disorders in the United States. Arthritis and Rheumatism 1998; 41: 778–799
- Lajas C, Abasolo L, Bellajdel B, et al. Costs and predictors of costs in rheumatoid arthritis: a prevalence-based study. Arthritis and Rheumatism 2003; 49: 64–70
- Wong JB, Ramey DR, Singh G. Long-term morbidity, mortality, and economics of rheumatoid arthritis. Arthritis and Rheumatism 2001; 44: 2746–2749
- Jacobsson LT, Lindroth Y, Marsal L, et al. Rheumatoid arthritis: what does it cost and what factors are driving those costs? Results of a survey in a community-derived population in MalmÖ, Sweden. Scandinavian Journal of Rheumatology 2007; 36: 179–183
- Lubeck DP. A review of the direct costs of rheumatoid arthritis: managed care versus fee-for-service settings. PharmacoEconomics 2001; 19: 811–818
- Theis KA, Helmick CG, Hootman JM. Arthritis burden and impact are greater among U.S. women than men: intervention opportunities. Journal of Women's Health (2002) 2007; 16: 441–453
- Gibofsky A, Palmer WR, Goldman JA, et al. Real-world utilization of DMARDs and biologics in rheumatoid arthritis: the RADIUS (Rheumatoid Arthritis Disease-Modifying Anti-Rheumatic Drug Intervention and Utilization Study) study. Current Medical Research and Opinion 2006; 22: 169–183
- Yelin EH, Criswell LA, Feigenbaum PG. Health care utilization and outcomes among persons with rheumatoid arthritis in fee-for-service and prepaid group practice settings. Journal of the Amercian Medical Association 1996; 276: 1048–1053
- Yelin E, Wanke LA. An assessment of the annual and long-term direct costs of rheumatoid arthritis. The impact of poor function and functional decline. Arthritis and Rheumatism 1999; 42: 1209–1218
- Robinson D, Jr, Hackett M, Wong J, et al. Co-occurrence and comorbidities in patients with immune-mediated inflammatory disorders: an exploration using US healthcare data, 2001–2002. Current Medical Research and Opinion 2006; 22: 989–1000
- Berg GD, Chattopadhyay SK. Determinants of hospital length of stay for cervical dysplasia and cervical cancer: does managed care matter? American Journal of Managed Care 2004; 10: 33–38
- Nissenson AR, Wade S, Goodnough T, et al. Economic burden of anemia in an insured population. Journal of Managed Care Pharmacy 2005; 11: 565–574
- Symmons DP. Looking back: rheumatoid arthritis—aetiology, occurrence and mortality. Rheumatology (Oxford, England) 2005; 44((Suppl. 4))iv14–iv17
- Gabriel SE, Crowson CS, O'Fallon WM. The epidemiology of rheumatoid arthritis in Rochester, Minnesota, 1955–1985. Arthritis and Rheumatism 1999; 42: 415–420
- Alamanos Y, Voulgari PV, Drosos AA. Incidence and prevalence of rheumatoid arthritis, based on the 1987 American College of Rheumatology criteria: a systematic review. Seminars in Arthritis and Rheumatism 2006; 36: 182–188
- Alamanos Y, Drosos AA. Epidemiology of adult rheumatoid arthritis. Autoimmunity Reviews 2005; 4: 130–136
- Doran MF, Pond GR, Crowson CS, et al. Trends in incidence and mortality in rheumatoid arthritis in Rochester, Minnesota, over a forty-year period. Arthritis and Rheumatism 2002; 46: 625–631